Alan Russell

Dr. Russell has founded three biotechnology companies and was Founding Director of the University of Pittsburgh’s McGowan Institute for Regenerative Medicine, Founding President of the Tissue Engineering and Regenerative Medicine International Society (TERMIS), and Founding Co-Director of the Armed Forces Institute for Regenerative Medicine.
Dr. Russell has participated on 24 scientific advisory boards and was the longest serving member of the Science Board to the U.S. Food & Drug Administration. He has received numerous awards, including R&D Magazine’s R&D 100 Award, three Carnegie Awards for Excellence, the American Chemical Society’s Pittsburgh Award, and the TERMIS Lifetime Achievement Award. He has published over 200 articles in refereed journals, as well as a book and 10 book chapters. He holds 14 patents and has more than 25 pending patents.

For individuals living with complex, often chronic conditions, and their families, palliative care can provide relief from symptoms, improve satisfaction and outcomes, and help address critical mental and spiritual needs during difficult times. Now more than ever, there is growing recognition of the importance of palliative care services for individuals with serious illness, such as advance care planning, pain and symptom management, care coordination, and team-based, multi-disciplinary support. These services can help patients and families cope with the symptoms and stressors of disease, better anticipate and avoid crises, and reduce unnecessary and/or unwanted care. While this model is grounded in evidence that demonstrates improved quality of life, better outcomes, and reduced cost for patients, only a fraction of individuals who could benefit from palliative care receive it. 























































































































































